Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Make a Passover gift and support Jewish journalism. DONATE NOW
The Schmooze

Sarah Jessica Parker Blasts EpiPen Maker For Jacking Up Prices

Sarah Jessica Parker came out on Instagram today officially announcing the end of her relationship with Mylan, the company that produces the EpiPen. SJP—whose son, James Wilkie, uses an EpiPen for his peanut allergy—had been involved in an initiative with Mylan to raise awareness for anaphylaxis, potentially life-threatening allergic reactions that the EpiPen (and the medicine it delivers, epinephrine) are designed to combat.

Parker stated that her decision to cut ties with Mylan is a “direct result” of the company’s recent price hikes regarding the cost of the EpiPen—and, looking at the numbers, she has a significant point. When Mylan started selling the EpiPen in 2007, it cost $57. Since then, the price has increased drastically each year, culminating in the recent announcement that the EpiPen would now be sold for over $500. That’s a price hike of over 400% in the span of nine years.

In her statement, SJP rightly accused the company of making the EpiPen cost prohibitive to “countless people”. She joined a large number of parents, educators, doctors, and general health and safety advocates who have been calling out Mylan for their actions, and it looks as if they may have had something of an impact. In a statement given to People Magazine today, Mylan said it would eliminate out-of-pocket expenses for uninsured and under-insured patients, and cover up to $300 of out-of-pocket costs at pharmacies.

It’s still not clear how much of that promise the company will actually fulfill, but good on SJP (and the many other people who raised their voices) for making a positive change. Because seriously, $500 for an EpiPen? That’s ridiculous. You go, girl.

Read SJP’s full post below:

A photo posted by SJP (@sarahjessicaparker) on

This is a moment of great uncertainty. Here’s what you can do about it.

This is a moment of great uncertainty for the news media, for the Jewish people, and for our sacred democracy. It is a time of confusion and declining trust in public institutions. An era in which we need humans to report facts, conduct investigations that hold power to account, tell stories that matter and share honest discourse on all that divides us.

With no paywall or subscriptions, the Forward is entirely supported by readers like you. Every dollar you give this Passover is invested in the future of the Forward — and telling the American Jewish story fully and fairly.

The Forward doesn’t rely on funding from institutions like governments or your local Jewish federation. There are thousands of readers like you who give us $18 or $36 or $100 each month or year.

Support our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:

  • Credit the Forward
  • Retain our pixel
  • Preserve our canonical link in Google search
  • Add a noindex tag in Google search

See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.